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Abstract Early-onset Parkinson’s disease (EOPD) has been
associated with recessive mutations in parkin (PARK2).
About half of the mutations found in parkin are genomic
rearrangements, i.e., large deletions or duplications. Al-
though many different rearrangements have been found in
parkin before, the exact breakpoints involving these rear-
rangements are rarely mapped. In the present study, the exact
breakpoints of 13 different parkin deletions/duplications,
detected in 13 patients out of a total screened sample of 116
EOPD patients using Multiple Ligation Probe Amplification
(MLPA) analysis, were mapped using real time quantitative
polymerase chain reaction (PCR), long-range PCR and
sequence analysis. Deletion/duplication-specific PCR tests
were developed as a rapid and low cost tool to confirm
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DOI 10.1007/s10048-011-0302-9MLPA results and to test family members or patients with
similar parkin deletions/duplications. Besides several differ-
ent deletions, an exon 3 deletion, an exon 4 deletion and an
exon 7 duplication were found in multiple families.
Haplotype analysis in four families showed that a common
haplotype of 1.2 Mb could be distinguished for the exon 7
duplication and a common haplotype of 6.3 Mb for the
deletion of exon 4. These findings suggest common founder
effects for distinct large rearrangements in parkin.
Keywords Parkinson’s disease.parkin.Deletion.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
classically characterized by the clinical triad of bradykinesia,
muscular rigidity and a resting tremor [1]. The mean age of
onset for PD and early onset PD (EOPD) is 60 and 45 years,
respectively [1, 2]. Autosomal recessive levodopa-responsive
EOPD can be caused by mutations in parkin (PARK2),
PINK1 or DJ-1 [2, 3]. Mutations in parkin are the most
common among the recessive forms of PD [2]. This gene
encodes Parkin, an E3 ubiquitin ligase. As part of the
ubiquitin proteosome pathway, Parkin can protect neurons
from cellular insults like alpha-synuclein toxicity and
protosomal dysfunction [4]. Recent findings revealed that
Parkin might also be involved in the development and/or
progression of ovarian and other cancers, suggesting that
parkin might also be a tumor suppressor gene [5, 6].
Since the cloning of parkin in 1998, a wide variety of
mutations has been identified in this gene [7, 8]. About
50% of the mutations found in parkin are small (point)
mutations detectable by sequencing. The remaining 50%
consists of genomic rearrangements, i.e., large deletions or
duplications [9, 10]. This high rearrangement rate can be
explained by the fact that parkin is located within the large
common fragile site (CFS) FRA6E [11]. CFS’s are reported
to be highly susceptible to genomic instability [11].
Although little is known about the role of CFSs, many of
the genes within these regions appear to function within the
stress response system and in normal neurological devel-
opment. The observation that extremely large genes,
located in an unstable region, are highly evolutionary
conserved suggests that these unstable regions and the
genes within share a role in normal cell function [11].
Since genomic sequencing is not suitable to detect large
rearrangements, other more quantitative methods are need-
ed for a sensitive screening of these genomic variants.
Available techniques include polymerase chain reaction
(PCR)-based amplifications to detect homozygous deletions
[3, 12], fluorescent dosage PCR [7], quantitative PCR (q-
PCR) [8, 13–15], microarray [16] and Multiple Ligation
Probe Amplification (MLPA) [17, 18]. MLPA is a rapid and
sensitive technique to detect alterations in copy numbers
using a multiplex PCR reaction. This method is suitable to
identify deletions/duplications in parkin [17, 18]. Although
many rearrangements have been found in parkin, the exact
breakpoints involving these rearrangements are rarely
mapped [3, 10, 12, 16]. In the present study, the breakpoint
mapping of 13 different parkin deletions/duplications as
found in 116 EOPD patients, is described. This approach
enabled the development of specific deletion/duplication
PCR’s as a rapid and low cost tool to confirm MLPA results
and to test family members or patients with similar parkin
deletions/duplications.
Materials and methods
Study population
The study population consisted of 116 patients whose
samples were sent to the DNA diagnostic laboratory
(Department of Clinical Genetics, Erasmus Medical Centre,
Rotterdam, The Netherlands) between March 12, 1999 and
February 3, 2010 for genetic screening of parkin. Samples
were sent by neurologists (n=89, 76.7%), clinical geneti-
cists (n=17, 14.6%) or other medical specialists (n=10,
8.6%) because of a clinical diagnosis or symptoms of
EOPD. The mean age of patients was 46.1 years (range 10–
80 years) at time of blood sampling. The majority of the
patients was male (n=71, 61%).
Mutation analysis
DNA was extracted from peripheral blood using the DNA
Blood Kit Special (Chemagen, Baesweiler, Germany),
which is based on DNA extraction and purification with
magnetic beads [19]. All 12 coding exons and exon/intron
boundaries of parkin (NM_004562.2, NCBI build 36
(UCSC hg18, March 2006)) were screened using direct
sequence analysis. SALSA MLPA kits P051 and P052
(MRC Holland, Amsterdam, The Netherlands) were used to
detect large rearrangements in parkin. MLPA analysis was
performed according to manufacturer’s instructions. MLPA
products were run on an ABI 3730XL automated sequencer
(Applied Biosystems, Foster City, CA, USA) and data was
analyzed using Genemarker software version 1.5 (Softge-
netics, State College, PA, USA).
q-PCR analysis
Real time quantitative PCR (q-PCR) was performed using
Fam labelled Taqman assays, designed with Primer Express
264 Neurogenetics (2011) 12:263–271version 2.0.0 (Applied Biosystems), around the deleted/
duplicated exons of parkin (NM_004562.2, NCBI build 36
(UCSC hg18, March 2006)). All primers were tested for
specificity by performing a BLASTn run. Taqman probes
were designed with an 8–10°C higher melting temperature
(Tm) than the primers. This was achieved by incorporating
locked nucleic acid (LNA) monomers in the probe [20].
LNA containing probes have an enhanced hybridisation
performance compared to classical Taqman probes and
allow a shorter probe design [20]. Tm calculations for LNA
incorporated probes were performed using the Exiqon Tm
prediction tool (http://www.exiqon.com/ls/homeoflna/
Oligo-tools/tm-prediction-tool.htm). LNA based Taqman
assays were manufactured by Eurogentec (Seraing, Bel-
gium). Gene dosage alterations were detected by
performing a relative quantification run on an ABI7500
real-time PCR system (Applied Biosystems). Real-time
PCR reactions were performed in a total volume of 25 μl,
containing 20 ng DNA, 1× q-PCR mastermix Pluslow
ROX (Eurogentec), 1× RNAse P (endogenous control)
(Applied Biosystems), 30 μM forward and reverse primer
and 10 μM probe. PCR conditions were initial 2 min 50°C
incubation, followed by 95°C for 10 min and 40 cycles of
95°C for 15 s and 60°C for 1 min. All samples were
analyzed in triplicate and compared to a normal control
sample as calibrator [21].
Long-range PCR
Long-range PCR was performed using the Expand Long
Template PCR System (Roche Applied Science, Indian-
apolis, IN, USA). PCR products were sequenced using the
ABI 3730XL automated sequencer (Applied Biosystems).
Data was analyzed using the Sequencing Analysis software
version 5.3.1 (Applied Biosystems).
Deletion/duplication specific PCR
For all deletions/duplications, a specific deletion/duplica-
tion-PCR test was designed using two primers (primers A
and B) flanking the deletion/duplication and one internal
primer (primer C; also see Table 1). Obtained PCR products
run on a 1.5% agarose gel will show a mutated allele and a
normal allele for a patient with a heterozygous deletion/
duplication, a mutated allele only for a patient with a
homozygous deletion/duplication and a normal allele only
for a non-affected individual.
Haplotype analysis
Haplotypes were constructed using nine polymorphic
microsatellite markers around the parkin locus. Three
markers were located within the intronic regions of parkin,
the remaining six markers were located 5′ and 3′ of parkin
on chromosome 6 (see Fig. 1). Markers were amplified
using standard conditions and reagents. Fam labelled PCR
products were run together with a LIZ-500 size standard on
an ABI 3730XL automated sequencer (Applied Biosys-
tems). Marker allele sizes were determined using Gene-
marker software version 1.5 (Softgenetics).
Results
A total of 116 patients with clinical symptoms of EOPD were
screened for mutations in parkin using direct sequencing and
MLPA analysis. In 13 patients (11%), at least one pathogenic
mutation was found (24 parkin mutations were found in
total). Eighty three percent (n=20) of the pathogenic
mutations consisted of large deletions/duplications, the
remaining 17% (n=4) consisted of point mutations or small
Table 1 Primers used for dele-
tion/duplication specific PCRs Mutation Primer A Primer B Primer C
Ex1del tctttgactgcctttgcatga tcacaactccctcaatgtcg ccctttaaaacggtgctcag
Ex2dup cccagttaccctgctgagaa agaagctgggttaaggagcc cttgctcttcacttcccagg
Ex2delA ttttctgttgcatttggctg gccttaccaccatttgctgt gtgtcttcctcctggtttcg
Ex2delB agccactggcatgttatcaa tgagtggatgcattcagttctc attggccatgttagggctc
Ex2delC tccagcttttagccactcttc caaccaaatctctgtatacccatca aaatgactgatttcagaaggaaatg
Ex3delA ccacctcttcatgcaatcac ggcaacaactgtcaaacagc aaattcttcagtgtagacaaacc
Ex3delB ccagtgtggtgtgtgagtcc tccaaagtggttccacatga tgacaccaccatgctcactt
Ex4del tacaagcttttaaagagtttcttgt cgtggttcaatccctcttgt aaaaccaactttgcgtcagg
Ex3-5del cattgttttgagggggaaat tcctcctaataatgataacaaagac catatcatcaatgcgcacagaa
Ex5del tctgaggctaggtcccttca tgtctttcggcctcagtgtatcta tcatgctgcattctggagac
Ex5-6del ggaggggaggtgactttctt gaggcgggtgagagattcta catgtgtgggcatacctcat
Ex7dup cagttcaaatccagtgttaccaa aagcaatgggtcattccgta ttccctttggtgcagtaacc
Ex8-10del tgtcacccaagtgccagttact tcagttgcttgtgcaacctc ttcacctcacctctcccaac
Neurogenetics (2011) 12:263–271 265deletions (e.g., a 2-bp deletion; data not shown). In Table 2,
the characteristics of 12 families of the (index) patients with
al a r g eparkin deletion/duplication are summarized (families
Tor-18-A and PV-24-A were reported before [22]). The
remaining patient has one point mutation and was excluded
from further analysis. Most of the patients with large
deletions/duplications have classical parkinsonism syn-
dromes like bradykinesia, hypokenetic rigidity and a resting
tremor. The mean age of onset of the patients listed in
Table 2 is 35.7 years. Table 3 gives an overview of all exon
deletions and duplications found in our study population
using MLPA analysis and breakpoint mapping.
To confirm the MLPA results with a different non-
quantitative technique and to study recurrent deletions/
duplications, the exact breakpoints of the rearrangements
were mapped using q-PCR analysis; long-range PCR analysis
and sequence analysis (see “Materials and methods” section).
Two examples of mapped rearrangements are shown in
Fig. 2a (exon 4 deletion, Ex4del) and Fig. 2b (exon 7
duplication, Ex7dup). Ex4del also includes an insertion of
28 bp, whereas Ex7dup includes an insertion of 7 bp
between the duplicated regions. The exact nomenclature of
all deletions/duplications in this study is given in Table 3.
For each exon deletion/duplication, a specific deletion/
duplication PCR test was developed based on the break-
point analysis results. Results of the specific deletion/
duplication PCR tests are shown in Fig. 3. Most patients
show a heterozygous pattern (both deletion/duplication
D6S1708
156.2
D6S1579
160.9
D6S305
162.1
D6S980
162.6
D6S1277
164.2
D6S386
168.7
Intron 7 Intron 3
D6S437
158.7
D6S1581
160.2
D6S955
162.4
Intron 4
parkin
6q25.3 6q27 6q26
Fig. 1 Schematic overview (not drawn to scale) of the polymorphic
microsatellite markers used for haplotyping. On top of the bars the
polymorphic microsatellite markers are depicted with their chromo-
somal marker positions in Mb according to NCBI build 36 (UCSC
hg18, March 2006)
Table 2 Characteristics of 12 families with a large parkin deletions/duplication
Family Age of onset Age at blood sampling Mutation 1 Mutation 2 Occurrence Clinical symptoms
A 48 74 Ex1del Ex3-5del S Hypokinetic rigid syndrome,
resting tremor, dyskinesia
B 58 59 Ex2dup
a R275W
a F Rigidity, hypokinesia, resting tremor
C 28 30 Ex2Adel Ex3Adel F Hypokinetic rigid syndrome, resting tremor,
dopamine-sensitive
D 37 42 Ex2Bdel Ex7dup S Bradykinesia in hand and legs, resting tremor
E 46 56 Ex2Cdel N/P S Hypokinetic rigid syndrome, tremor, bradykinesia
F 38 42 Ex3Bdel 101delAG F Mild bradykinesia and rigidity, stooped posture,
no dystonia
G 16 47 Ex3Bdel R275W S Hypokinetic rigid syndrome, resting tremor
arms and legs, dystonia
H II.1 45 45 Ex4del Ex7dup F II.1 Hypokinetic rigidity, dystonia
II.3 38 42 Ex4del Ex7dup II.3 Parkinsonism, dystonia
II.5 33 39 Ex4del Ex7dup II.5 Parkinsonism, dystonia
I 20 50 Ex4del Ex7dup F Hypokinetic rigid syndrome, dopamine-sensitive
J II.4 52 54 Ex5-6del N/P F II.4: Tremor and rigidity right arm
III.1 22 47 Ex5-6del Ex7dup III.1: Tremor feet and right hand/rigidity
III.2 33 37 Ex5-6del Ex7dup III.2 Rigidity/dyskinesia
Tor-18-A 38 52 Ex5del Ex5del F Bradykinesia, rigidity and tremor
PV-24-A 20 39 Ex8-10del Ex8-10del S Bradykinesia, rigidity and tremor
S sporadic, F familial, N/P not present
aLocated on the same allele
266 Neurogenetics (2011) 12:263–271Table 3 Overview of the large
parkin deletions/duplications
found in this study
Del deletion, dup duplication
aNumbering according to NM_00
4562.2, NCBI build 36 (UCSC
hg18, March 2006)
bPreviously reported deletion [10]
cPreviously reported families [22]
Family Mutation Exon Del/dup HGV nomenclature
a
A Ex1del 1 Del c.-17782_7+123791del141580
B Ex2dup 2 Dup c.8-51502_172-33560dup198650insT
C Ex2delA 2 Del c.8-61987_171+4006del66157
D Ex2delB 2 Del c.8-48180_171+84346del132690
E Ex2delC 2 Del c.8-18045_172-62803del135951ins33
C Ex3delA 3 Del c.172-5243_412+18307del23791
F/G Ex3delB 3 Del c.172-4427_413-6108del59833
H/I Ex4del
b 4 Del c.413-26603_534+367del27092ins28
A Ex3-5del 3–5 Del c.171+11347_618+17328del 395200
Tor-18-A
c Ex5del 5 Del c.535-49422_619-12906del117274
J Ex5-6del 5–6 Del c.534+17825_735-64158del333241
D/H/I/J Ex7dup 7 Dup c.734+61166_871+2877dup129242ins7
PV-24-A
c Ex8-10del 8–10 Del c.872-60873_1167+2393del245828
TAGAGGAACA caaccttagtgt tctgtgtgat GGTAGCATGG
Insertion 28 bp
TGAATTCAATAGAGGAAATTTCAATAGA
Deletion27092 bp
Exon 7
ATTTTTTAATTGCAGTGTGAT
b b
Insertion 7 bp
c
Exon 7 WT
dup Exon 7
a a
a
b
Exon 4
Fig. 2 Schematic overview of
the breakpoint analysis results of
Ex4del (A) and Ex7dup (B).
Retained sequences are shown
in capitals, deleted nucleotides
are shown in lower case,
inserted nucleotides are in italic.
Indicated for Ex7dup are the 5′
(vertically hatched) and 3′
flanking regions (horizontally
hatched) that are duplicated
together with exon 7, and the
primers (a, b and c) used for the
specific duplication PCR test
(see “Materials and methods”).
WT wild-type, dup duplication
Neurogenetics (2011) 12:263–271 267band and wild-type band present), whereas for Ex5del and
Ex8-10del a homozygous pattern was observed (only
mutant band visible).
Most of the exon deletions/duplications appear to be
unique, but three exon deletions/duplications (Ex3delB,
Ex4del and Ex7dup) were found among multiple families
(see Table 3). Three index patients had an exon 2 deletion
(Table 3; families C, D and E), but the breakpoints were
different. Three index patients had an exon 3 deletion of
which two types were found (Table 3; families C, F and G).
Four index patients had the same Ex7dup (Table 3; families
D, H, I and J), whereas 2/4 index patients also shared the
same Ex4del (Table 3; families H and I). All available
family members of families D, H, I and J were screened
with the specifically developed deletion/duplication PCR
test. These screening results are shown in Fig. 4.
Haplotypes were constructed around the parkin locus to
investigate whether a common haplotype was present
among the four families with the same Ex7dup mutation
(Table 3; families D, H, I and J). Results of the haplotype
analysis are presented in Fig. 4. For Ex7dup a shared
haplotype was identified of at least 1.2 Mb as characterized
by markers D6S1579 and D6S305. Ex4del shares a
common haplotype of at least 6.3 Mb characterized by
D6S955 to D6S386. Ex5-6del shares a common haplotype
of at least 5.9 Mb characterized by D6S1708 to D6S305
found in one family only. Ex3del was found in two families
(Table 3; families F and G), but for this mutation no
common haplotype was found (data not shown).
Discussion
Over the past 11 years, 116 patients with early-onset
Parkinson disease (EOPD) have been referred to our
laboratory for genetic screening of parkin. Mutations were
found in 13 patients with an overall mutation rate of 11%,
which is slightly higher than reported before [14, 18, 23].
Multiplex Ligation-dependent Probe Amplification
(MLPA) analysis was used in this study to screen for large
deletions/duplications in parkin, because of its effectiveness
to detect homo- and heterozygous deletions/duplications in
parkin in a multiplex way. The MLPA technique is however
prone to false positive results because of the possibility of
polymorphisms on probe locations. Therefore, all deletions/
duplications found need to be confirmed using a different
technique [17, 23]. Our result that 83% of the mutations
found in parkin consist of large deletions/duplications is
higher than described previously [2, 14, 17, 18]. This
finding clarifies that gene dosage studies are essential in
parkin mutation screening. The high rate of large rearrange-
ments might be explained by recurrent deletions/duplica-
tions in our study group or by the effectiveness of the
MLPA technique to detect exon deletions/duplications
compared to other techniques. Mapping of the exact
breakpoints enables us to confirm MLPA results with a
non-quantitative method and to compare the found dele-
tions/duplications with other deletions/duplications in par-
kin. For all 13 different large deletions/duplications, a
specific deletion/duplication-PCR test was developed as a
low cost, quick, and robust technique to confirm MLPA
results and to test other family members for the specific
mutation or patients with similar MLPA results.
Only a few researchers have taken the effort to locate the
exact breakpoints of large rearrangements found in parkin
[3, 10, 12, 16], most likely because it is time-consuming as
parkin is among the largest known genes with intronic
regions up to 284 kb [11]. Four different exon 4 deletions
were mapped before by two research groups [3, 10]. Ex4del
in two of our patients (Fig. 2a) turned out to be the same
deletion as reported by Hedrich et al. [10] in patients from
Italy and Northern Germany. The compound heterozygous
Fig. 3 Results of all 13 dele-
tion/duplication specific PCR
tests for patients (P) versus
CEPH controls (C). Samples
were run on a 1.5% agarose gel
together with a 1-kb DNA
ladder (first lane; Invitrogen,
Carlsbad, CA, USA). PCR
products of the mutated alleles
are smaller than PCR products
of the normal alleles. Some
background PCR bands are
visible for Ex2dup (above nor-
mal band of 791 bp) and
Ex2delA (below mutant band of
873 bp)
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I.1
D6S1708 159 155 155 159
D6S437 149 149 127 127
D6S1581 228 226 214 218
D6S1579 145 143 145 143
D6S305 223 225 223 223
D6S955 143 152 147 143
D6S980 288 298 294 284
D6S1277 291 295 303 299
D6S386 160 160 168 168
II.1 II.2 II.3 II.4 II.5
Ex 4 del +/-
Ex 7 dup +/-
Ex 4 del -/-
Ex 7 dup +/-
Ex 4 del +/-
Ex 7 dup +/-
Ex 4 del -/-
Ex 7 dup +/-
Ex 4 del +/-
Ex 7 dup +/-
159 159 155 159 159 159 155 159 159 159
149 127 149 127 149 127 149 127 149 127
228 218 228 218 228 218 228 218 228 218
1 4 51 4 3 1 4 31 4 3 1 4 51 4 3 1 4 31 4 3 1 4 51 4 3
223 223 225 223 223 223 225 223 223 223
143 143 152 143 143 143 152 143 143 143
288 284 298 284 288 284 298 284 288 294
291 299 295 299 291 299 295 299 291 303
160 168 160 168 160 168 160 168 160 168
II.6
Ex 4 del -/-
Ex 7 dup +/-
155 159
149 127
228 218
143 143
225 223
152 143
294 298
295 303
160 168
Fam D
Fam J Fam I
Fam H
I.2
I.1
Ex 4 del +/-
Ex 7 dup +/-
Ex 2 delB +/-
Ex 7 dup +/-
I.2
Ex 4 del -/-
Ex 7 dup +/-
Ex 4 del +/-
Ex 7 dup -/-
159 169
169 171
127 127
127 157
226 218
226 228
143 143
153 143
227 223
203 223
143 143
138 156
288 284
286 291
291 299
295 299
160 160
148 172
Ex 4 del +/-
Ex 7 dup -/-
II.1
159 169
127 127
226 228
143 155
227 227
143 138
288 291
291 295
160 156
II.1 II.2 II.3 II.5 II.4
Ex 5-6 del +/-
Ex 7 dup -/-
Ex 5-6 del +/-
Ex 7 dup -/-
Ex 5-6 del +/-
Ex 7 dup -/-
155 155 155 169 155 155
149 127 149 127 149 127
218 218 218 218 218 218
143 155 143 151 143 155
219 223 219 219 219 223
147 147 156 156 147 147
295 295 291 295 295 295
295 299 299 299 295 299
160 168 160 168 160 168
III.1 III.2
Ex 5-6 del +/-
Ex 7 dup +/-
Ex 5-6 del +/-
Ex 7 dup +/-
155 157 155 157
149 157 149 157
218 228 218 228
143 143 143 143
219 223 219 223
156 156 156 156
291 295 291 295
291 299 291 299
148 160 168 168
Fig. 4 Four EOPD pedigrees with the same Ex7dup. Individuals with
EOPD are depicted with filled symbols, half-filled symbols represent
carriers of one mutated allele and open symbols represent individuals
with an unknown PD history. Index patients are indicated with an
arrow. Results of the deletion/duplication specific tests are given for
each individual as −/−; no deletion/duplication detected or +/−;
heterozygous deletion/duplication. Also indicated for each individual
are the nine markers with corresponding allele sizes. Common
haplotypes for Ex4del, Ex5-6del and Ex7dup are depicted as a black
box, white box or grey box, respectively
Neurogenetics (2011) 12:263–271 269mutations of a deletion of exon 4 and a duplication of exon
7, as we found in families H and I, were reported
previously in a Dutch patient [18]. In this patient, the
reported mutations also occurred familial. Bayrakli et al.
[16] mapped the breakpoints of an exon 5 deletion, but this
deletion differs from the Ex5del found in our study. A
duplication of exon 7 was reported by other researchers [7,
10, 18, 24–26], but was never mapped. Therefore, it
remains undetermined whether these exon 7 duplications
are identical. Most of the deletions/duplications listed in
Table 3 are frameshift mutations that lead to a premature
stopcodon several positions downstream. The only excep-
tion is Ex3-5del, which results in the loss of 149 residues.
These residues are part of the Ubiquitin Like Domain
(UBL) and the Src Homology 2 like (SH2-like) domain [6].
Although the exact function of these domains is still
unclear, it is to be expected that the loss of 149 residues
will lead to a loss of function of Parkin [6].
Similar haplotypes based on markers in the parkin region
would support the hypothesis of a common founder effect
multiple generations ago. The haplotype analysis (see Fig. 4)
indicated that for Ex7dup a common haplotype of 1.2 Mb
was present in four families, whereas a common haplotype
of 6.3 Mb was present for Ex4del in two families. These data
support the hypothesis of a common founder effect for
mutations in parkin as reported before [10]. In autosomal
recessive disease, founder mutations are commonly observed
since in general there is no selection against carriers of
mutations. Periquet et al. [27] reported a founder effect for
some parkin point mutations, exon rearrangements were
reported as independent recurrent events. It is unclear
whether any of the exon rearrangements described by
Periquet et al. are identical to ours since the deletions/
duplications breakpoints were not mapped in their study.
A comprehensive literature overview among 379 unre-
lated carriers of parkin mutations showed a relatively high
rate of exon deletions and duplications between exons 2
and 9 of parkin [10]. This is in line with the finding that the
most unstable region in the CFS FRA6E was determined
between exons 2 and 8 of parkin, suggesting hotspots for
forming gaps and breaks in the large intronic regions [5]. In
contradiction to this finding we found that in some cases
(families D/H/I/J for Ex7dup; families F/G for Exdel3B and
families H/I for Ex4del) deletions/duplications shared
similar breakpoints (see Table 3), indicating a common
founder effect. Our data provides evidence that, besides
mutational hotspots, also common founder mutations are a
source of exon rearrangements in parkin.
The parkin mutations found in pedigrees D, H and I
follow a recessive inheritance pattern. In family J the
difference between the affected patient II.4 and the
unaffected individuals II.1 and II.2 who all share the same
ex5-6del and are about the same age, remains unclear. The
affected patient II.4 was negative for mutations in LRRK2,
SNCA, PINK1 and DJ-1. It is possible that this patient has a
second yet undiscovered mutation in a PD related gene. It is
also possible that a single heterozygous mutation in a
recessive gene like parkin is sufficient to cause PD or at
least to increase the risk of developing the disease [2].
Individuals II.3 and II.5 of family J and individual I.1 of
family I were unfortunately not available for study. For
family D, only the index patient was available for testing.
Inconclusion,withthedevelopmentofmultiplexscreening
techniques like MLPA, an increasing amount of rearrange-
ments willbefoundinEOPD patients.Inthe present studywe
demonstrate that breakpoint mapping of parkin deletions/
duplications can be useful to compare exon rearrangements
between patients and families and to study a possible founder
effect. Using this approach we have identified common
haplotypes for an exon 7 duplication and an exon 4 deletion.
Furthermore, we also show that deletion/duplication-specific
PCR tests can be developed as a rapid and low cost tool to
confirm MLPA results and to test family members or patients
with similar parkin deletions/duplications.
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